Pneumonia News and Research

Latest Pneumonia News and Research

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

New insight into causes of childhood pneumonia

The scientific journal Clinical Infectious Diseases has released its March Special Supplement focusing entirely on the research design of and pilot data from the Pneumonia Etiology Research for Child Health (PERCH) Project, which seeks to identify the causes of pneumonia among the world's most vulnerable populations.

12 Mar 2012

Concerns about aging in good health

Do men harbour concerns about aging in good health? Do they confide these concerns to their physicians? Are men's concerns the same as women's? The answers to these questions can be found in a large cross-sectional survey of 2325 Canadian men, aged 55 to 97 years old, led by Dr. Cara Tannenbaum, Geriatrician and the Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging at the Institut universitaire de gériatrie de Montréal (IUGM) which is affiliated with the Université de Montréal.

10 Mar 2012

Reducing consumption of antimicrobial agents reduces resistance: DANMAP

Antimicrobial agents are the most important weapons in the fight against bacterial infections in humans and animals, but these agents can lose their potency. When bacteria are exposed to antimicrobial agents they can develop resistance. This would make it more difficult to treat common diseases such as pneumonia and other infections.

8 Mar 2012

NEJM publishes results from two Jakafi Phase III studies on MF

The New England Journal of Medicine (NEJM) today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis.

1 Mar 2012

Breakthrough discovery about Rhizobium radiobacter

A new discovery involving two Simon Fraser University scientists could lead to a little known and benign bacterium becoming a vital new tool in the development of a vaccine against human immunodeficiency virus.

29 Feb 2012

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

WHO urging Afghans to vaccinate children for measles following outbreak in western region

The WHO "is calling on all Afghans to vaccinate their children after a recent measles outbreak that has been made worse by severe weather that hampers access to immediate treatment as well as low immunization coverage," the U.N. News Centre reports.

24 Feb 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low dose dexamethasone in patients with relapsed multiple myeloma.

23 Feb 2012

Intramuscular midazolam effective in treating status epilepticus

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher.

17 Feb 2012

Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

14 Feb 2012

Grand Challenges Canada, Gates Foundation announce grants for innovative Global Health projects

"Grand Challenges Canada on Thursday announced 15 grants valued in total at more than $1.5 million awarded to some of Canada's most creative innovators from across the country in support of their work to improve global health conditions," according to a press release from the Sandra Rotman Centre for Global Health, which hosts Grand Challenges.

13 Feb 2012

Grand Challenges Canada announces 15 grants to support rising stars in global health

Grand Challenges Canada today announced 15 grants valued in total at more than $1.5 million awarded to some of Canada's most creative innovators from across the country in support of their work to improve global health conditions.

10 Feb 2012

Asian bird flu update for Ferbruary 2012

Health workers in Nepal are to cull thousands of chickens following the discovery of the H5N1 strain of bird flu in the southeastern part of the Himalayan country.

6 Feb 2012

New MRSA ‘superbug’ worries experts

A deadly mutant bug could be spreading among the public warn experts. The deadly strain of Methicillin-Resistant Staphylococcus Aureus (MRSA) called USA300 passes easily through skin-to-skin contact. It can also survive on surfaces and so has the potential to be picked up on crowded buses and tubes. The first cases were seen in the US but cases are now being reported in the community and not just hospitals in Britain.

3 Feb 2012

Potential way to block second wave of death from pneumonia treatment

An international research team may have found a way to block a second wave of death that can result from pneumonia treatment.

1 Feb 2012

Certain strains of P. aeruginosa cause WBCs to produce high levels of histamine

Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation.

1 Feb 2012

Study investigates how bacteria change their disguise to evade vaccines

Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail. The study, published today in Nature Genetics, which investigates how bacteria change their disguise to evade the vaccines, has implications for how future vaccines can be made more effective.

30 Jan 2012